An overview of anticoagulants, antiplatelet agents, and the combination in patients with mechanical heart valves

Journal of Heart Valve Disease

Volumn 13, Issue 3, 2004, Pages 319-324

  Bussey, Henry I ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

DRUG COMBINATION; HEART VALVE PROSTHESIS; HUMAN; REVIEW; THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG THERAPY, COMBINATION; HEART VALVE PROSTHESIS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM;

EID: 5144221044     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17
2. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S
3. Olsson SB. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (DPORTIF III) Lancet 2003;362:1691-1698
4. Halparin JL. SPORTIF III: A long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation ("late breaking" trials presentation at American College of Cardiology 2003 Scientific Session available online: http://www.acc03online.acc.org/onde-mand/trials3/sessions.asp?sid=3
5. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119:220S-227S
6. Kamath S, Blann AD, Chin BSP, Lip GYH. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin indices on thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002;40:484-490
7. Schlitt A, von Bardeleben RS, Ehrlich A, et al. Clodipogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res 2003;109:131-135
8. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993;329:524-529
9. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA. Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: A randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997;113:910-916
10. Laffort P, Roudaut R, Roques X, et al. Early and long-term (one-year) effects of the association of aspirin and oral anticoagulation on thrombi and morbidity after replacement of the mitral valve with the St. Jude Medical prosthesis. J Am Coll Cardiol 2000;35:739-746
11. Turpie AGG, Gent M, Cruickshank MK, et al. Randomized comparison of moderate (INR 3.0-3.5) with low intensity (INR 2.0-3.5) anticoagulation therapy in patients with prosthetic heart valves treated with aspirin (100 mg/day) (abstract #4026). Circulation 1998;98(Suppl. 1):768
12. Laas J, Kseibi S, Perthel M, Klingbeil A, El-Ayoubi L, Alken A. Impact of high intensity transient signals on the choice of mechanical aortic valve substitutes. Eur J Cardiothorac Surg 2003;23:93-96
13. Kleine P, Perthel M, Hasenkam JM, Nygaard H, Hansen SB, Laas J. Downstream turbulence and high intensity transient signals (HITS) following aortic valve replacement with Medtronic Hall or St. Jude Medical valve substitutes. Eur J Cardiothorac Surg 2000;17:20-24
14. Gencbay M, Tuyran F, Yaymaci Bdegertekin M, Basaran Y, Dindar I, Izgi A. Prevalence of microbub-bles associated with mechanical prosthetic heart valves: A prospective transesophageal echocardiography study. J Heart Valve Dis 1998;7:340-344
15. Sliwka U, Georgiadis D. Clinical correlation of Doppler microembolic signals in patients with prosthetic cardiac valves: Analysis of 580 cases. Stroke; J Cereb Circ 1998;29:140-143
16. Rams JJ, Davis DA, Lolley DM, Berger MP, Spencer M. Detection of microemboli in patients with artificial heart valves using transcranial Doppler: Preliminary observations. J Heart Valve Dis 1993;2:37-41
17. Geiser T, Sturzenegger M, Genewein U, Haeberli A, Beer JH. Mechanism of cerebrovascular events as assessed by procoagulant activity, cerebral microemboli, and platelet microparticles in patients with prosthetic heart valves. Stroke; J Cereb Circ 1998;29:1770-1777
18. Kofidis T, Fisher S, Leyh R, et al. Clinical relevance of intracranial high intensity transient signals in patients following prosthetic aortic valve replacement. Eur J Cardiothorac Surg 2002;21:22-26
19. Sturzenegger M, Beer JH, Rihs F. Monitoring combined antithrombotic treatments in patients with prosthetic heart valves using transcranial Doppler and coagulation markers. Stroke; J Cereb Circ 1995;26:63-69
20. Deklunder G, Roussel M, Lecroart JL, Porat A, Gautier C. Microemboli in cerebral circulation and alteration of cognitive abilities in patients with mechanical prosthetic heart valves. Stroke; J Cereb Circ 1998;29:1821-1826